Why the Mounjaro dose increases — and what the evidence says

What the trial data actually showed about dose and outcome

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised thousands of adults with obesity across multiple tirzepatide doses. Weight loss at 5mg and 10mg was meaningful, but the 15mg arm consistently produced the largest average reduction, around 20–21% over 72 weeks. That dose-response relationship is the scientific reason titration matters, and it is not that higher doses work differently in kind; they work more intensively in degree. GIP and GLP-1 receptor engagement increases with concentration, driving stronger appetite suppression and slower gastric emptying.

Importantly, participants did not start at 15mg. They reached it through a structured schedule. The researchers designed it that way deliberately, because early high-dose exposure produced more GI side effects without improving tolerability. The trial architecture is effectively built into the licensed dosing schedule you see today.

For a full picture of what the evidence says about how tirzepatide works and what it is licensed for, that overview covers the mechanism in more depth.

Why 2.5mg is where treatment begins, not where it ends

The 2.5mg starting pen exists for one reason: to let your digestive system adjust before a therapeutically active concentration builds up. Tirzepatide slows gastric emptying significantly. At a full maintenance dose from day one, most people would experience nausea, vomiting or diarrhoea intense enough to abandon treatment. The starter dose reduces that risk substantially.

This is described plainly in the NHS medicines information for tirzepatide: the dose starts low and is increased gradually, typically in four-week steps, as directed by your prescriber. The steps (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg) are not arbitrary. Each four-week interval gives your body time to reach steady state at the current dose before moving higher.

In practice, this means some people spend several months at lower doses before reaching the level that produces their best response. That is normal and expected. Questions about your individual pace come up regularly in aftercare; our prescribers address them case by case. If you want to understand the reasoning behind a specific step, the guidance on when to move up a Mounjaro dose covers the clinical signals a prescriber looks for.

What happens biologically as the dose rises

Tirzepatide activates two receptors simultaneously, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. This dual-agonist profile is what makes Mounjaro the only medicine of its kind currently licensed for weight management in the UK. As the dose increases, receptor engagement deepens. Appetite signals reaching the brain are suppressed more consistently, the speed at which food leaves the stomach slows further, and post-meal satiety lasts longer.

The result is that many people find their natural portion size falls, cravings for energy-dense food reduce, and the discomfort of eating less diminishes. These effects are dose-dependent: they strengthen as titration progresses. That is why NICE, in its technology appraisal TA1026 for tirzepatide, recommends reviewing continuation if less than 5% weight loss is achieved after six months at the highest tolerated dose. The evidence simply does not support maintaining a dose that is not producing a response.

Side effects tend to peak after each dose increase and then settle, usually within a few days to two weeks. Nausea, loose stools and fatigue are the most commonly reported. Severe or persistent stomach pain that radiates to the back should be reported to a clinician promptly, as this can be a sign of pancreatitis, which the MHRA has flagged as a rare but serious consideration for GLP-1 medicines.

What a prescriber looks for before approving an increase

A dose increase is not automatic. Before authorising a step up, a prescriber needs to know that the current dose is being tolerated, that any early side effects have settled, and that there is a clinical reason to move higher. Good progress on weight and tolerability generally supports moving to the next pen. Persistent nausea or vomiting at the current level is usually a reason to stay put until things settle.

Transfer patients arriving with evidence of an existing dose may progress differently to someone starting from scratch. Similarly, people who reach 7.5mg or 10mg and find their weight loss has plateaued may need a further increase to maintain momentum. The process for increasing your Mounjaro dosage and what that clinical review involves is covered separately.

One practical note: timing can matter more than people expect. Ordering a dose-increase pen mid-month, over a bank holiday, or just before going away can create a gap at the wrong moment in your titration. Planning your next pen around the 12pm dispatch cut-off on a working day keeps things on track. If you are unsure how to time a dose change, or want to discuss whether you are ready to move up, our prescribers at the consultation page can review your progress and advise.

For context on the first therapeutic Mounjaro pen at 5mg and what changes from the starter dose, that page covers what to expect at that step. And if you are curious about how tirzepatide dose increases are managed more broadly, including what the SmPC says, that resource goes into the pharmacological detail.